WOE of Anti-CD20 Therapies

The nature, intensity, and prevalence of this wearing-off effect remain poorly
understood. To our knowledge, there is no consensus in the literature on what symptoms
constitute a wearing-off effect, nor is there a single validated scale that measures
wearing-off effect. The current study will explore the wearing-off effect associated with
OCR and OMB, using a variety of validated scales assessing MS symptoms (i.e., fatigue,
mobility, pain, depression, cognition), as well as some global questions on wearing-off.
In addition, impact of worsening of MS symptoms on patients' health-related quality of
life (HRQoL) and their work productivity will be assessed using relevant MS-specific
validated scales This will be a non-interventional, primary data collection study in patients with MS
treated with an established anti-CD20 treatment regimen (OCR or OMB) in the United
States. Patients who satisfy the inclusion criteria and consent to participate in the
study will be surveyed at four timepoints at the beginning and the end of OCR or OMB
treatment cycles according to the following assessment schedule:

- Assessment 1. 0-10 days before 1st dose post-enrollment (index dose)

- Assessment 2: 5-14 days after index dose

- Assessment 3: 0-10 days before 2nd dose post-enrollment (follow-up dose)

- Assessment 4: 5-14 days after follow-up dose dose